Effect of Menatetrenone, a Vitamin K₂ Analog, on Recurrence of Hepatocellular Carcinoma after Surgical Resection: A Prospective Randomized Controlled Trial

Cumulative disease-free survival rates. A: The cumulative disease-free survival rates at 12, 24, 36, 48, and 60 months in the non-menatetrenone (MNT) group were 70.6%, 49.6%, 26.3%, 26.3%, and 26.3%, respectively, whereas those in the MNT group were 71.9%, 51.9%, 44.5%, 33.0%, and 26.4%, respectively (p=0.483). B: In patients with a preoperative Des-γ-carboxy-prothrombin (DCP) level lower than 40 AU/l, the cumulative disease-free survival rates at 12, 24, 36, 48, and 60 months in the non-MNT group (squares) were 81.3%, 44.7%, 0.0%, 0.0%, and 0.0%, respectively, whereas those in the MNT group (triangles) were 78.3%, 66.4%, 58.1%, 40.0%, and 31.0%, respectively (p=0.060). C: In patients with a preoperative DCP level higher than 40 AU/l, the cumulative disease-free survival rates at 12, 24, 36, 48, and 60 months in the non-MNT group were 65.7%, 51.1%, 35.7%, 35.7%, and 35.7%, respectively, whereas those in the MNT group were 64.3%, 38.4%, 32.0%, 32.0%, and 21.3%, respectively (p=0.511). D. cumulative disease-free survival rates in patients positive for only HCV, and not for HBV. The disease-free survival rates at 12, 24, 36, 48, and 60 months for these patients were 93.3%, 60.0%, 17.1%, 17.1%, and 17.1% in the non-MNT group, and 71.4%, 40.8%, 40.8%, 27.2%, and 27.2% in the MNT group, respectively (p=0.637).